Santariškių g. 2, 08661 Vilnius
tel. (+370) 5 236 5000
faks. (+370) 5 236 5111
info@santa.lt

      

SANTAROS KLINIKOS

VILNIAUS UNIVERSITETO LIGONINĖ

Scientific activity

Spausdinti

A priority direction of HOTC (Hematology, Oncology and Transfusion Medicine Centre) is development of biomedical studies in order to stimulate medical innovations, so patients can receive treatment based on the latest technology. HOTC organizes and develops epidemiological, diagnostic studies.

HOTC cooperation with international organizations:

Organization

Admission date

HOTC status

Nuoroda

Pavadinimas

NMSGwww.nordic-myeloma.org


Nordic Myeloma Study Group


 2015

 

Member/ Research centre

HOVON

www.hovon.nl

Haemato Oncology Foundation for Adults in the Netherlands

2014

Research centre

1e

www.eortc.org

European Organisation for Research and Treatment of Cancer

2012

Member/ Research centre

2e
www.nopho.org

Nordic Society of Pediatric Haematology and Oncology

2010

Research centre

3e

www.leukemia-net.org

European Leukemia Net

 

2010

Member

4e

www.ebmt.org

European Group for Blood and Marrow Transplantation

2003

Member

On HOTC‘s initiative Hematology Monitoring System (HMS) was designed. It is a system where information about newly diagnosed cases of blood cancer is stored. Moreover, this system helps to track the progress and treatment efficacy of such diseases. Using HMS collected data is analyzed and the results are used for drawing conclusions about the epidemiology of cancer, efficacy of applied treatment, tendencies.

Physicians of the Centre regularly participate in international conferences where they can find out latest medical news, present diagnostic capabilities of HOTC and treatment outcomes. Also, the Centre is involved in activities of Lithuanian Society of Hematologists (LSH), organizes conferences and Lithuanian and foreign specialists are invited there.

HOTC biomedical studies

 

Study object

Study title

Type of study

Bioethics Committee Approval date, No / EudraCT No.

Authority

Hematology

AML  and high risk MDS

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years.

 

Interventional

2017-05-22,

Nr. PP-114

 

EudraCT Nr.

2015-002855-85

 

HOVON

High risk acute leukemia

Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia

Interventional

2016-12-22,

Nr. P-16-72

 

EudraCT Nr.

2009-012973-37

MolMed S.p.A.

Relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Interventional

2016-10-24,

Nr. P-16-62

 

EudraCT Nr.

2016-002739-14

 

Sanofi-aventis

Multiple myeloma

Phase II study of carfilzomib-cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfilzomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with autologous stem cell support

Interventional

2016-03-21,

Nr. P-16-15

 

EudraCT Nr. 2013‐003789-15

Nordic Myeloma Study Group

Graft versus host disease

Study of medical care and clinical course and of graft versus host disease  (No: TPSL-LTU-2015)

Retrospective-prospective, observational

2015-11-03; Nr. 158200-15-814-326

Hematology and Oncology Research Association LTU

Chronic lymphocytic leukemia

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Interventional

2015-06-25, Nr. P-15-43/1

 

EudraCT Nr.: 2014-005582-73

Acerta Pharma B. V.

Paroxysmal nocturnal hemoglobinuria (PNH)

 

An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti-C5 monoclonal antibody in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Interventional

2015-06-25, Nr. P15-39

 

EudraCT Nr.: 2014-005338-74

 

Novartis Pharma Services AG

Acute myeloid leukemia

EORTC-1301-LG: 10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group. EudraCT Nr.: 2014-001486-27

Interventional

2014-12-19,
Nr. P-14-69

 

EudraCT Nr.: 2014-001486-27

 EORTC

Acute myeloid leukemia

Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5).

 

Interventional

2014-07-23, Nr. P-14-42

 

EudraCT Nr.: 2013-002843-26

HOVON

Thrombotic microangiopathy

A phase 2, uncontrolled, two-Stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombotic microangiopathies

Interventional

2014-07-17, Nr. P-14-36/2

 

EudraCT Nr.: 2014-001032-11

Omeros Corporation

Chronic lymphocytic leukemia

 

A multicenter, open-label, single-arm, phase III B, international study evaluating the safety of obinutuzumab alone or in combination with previously untreated or relapsed/refractory chronic lymphocytic leukemia

Interventional

2014-05-21, Nr. PP-102

 

EudraCT Nr.: 2013-000087-29

UAB „Roche“ Lietuva

Hemophilia A

 

A fhase 3b  continuation study of the safety and efficacy of PEGylated recombinant factor VIII (PEG-rFVIII; BAX 855) in prophylaxis of bleeding in previously treated with severe hemophilia A

Interventional

2013-10-21, Nr.P-13-77/1

 

EudraCT Nr.: 2013-001359-11

 

Baxter Innovations GmbH

Multiple myeloma

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With

Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly

Diagnosed Multiple Myeloma

Interventional

2013-09-06, Nr. P-13-65/2

 

EudraCT Nr.: 2010-020454-34

Amgen Aktiebolag

Multiple myeloma

Study of  bone marrow malignant plasma cells‘ clone of adhesive immunophenotype and genetic aberrations links to circulating plasma cells. (PLAG-LTU 2012)

Prospective, non-interventional

2013-02-12, Nr. 158200-13-587-177

 

Hematology and Oncology Association of Investigators LTU

Primary myelofibrosis

Populational clinical and genetic analysis of patients with primary myelofibrosis of Lithuania ( No: PMF-LTU-01)

Observational

2012-11-29, Nr. 158200-12-545-156

Hematology and Oncology Association of Investigators LTU

Acute lymphoblastic leukemia

NOPHO ALL-2008 Treatment protocol for young adults (18-45 years of age) for  Acute Lymphoblastic Leukemia.

 

Interventional

2011-05-24, Nr. P-11-43

 

EudraCT Nr.: 2011-000908-18

Nordic Society of Paediatric Haematology and Oncology

Oncology

Advanced metastatic soft tissue sarcoma

A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based first line chemotherapy for inoperable disease "ANITA"

Interventional

2017-08-29,

Nr. P-17-42

 

EudraCT Nr.:

2016-002093-12

EORTC

Gastric/ Gastroesophageal Junction (GEJ) Adenocarcinoma

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventional

2015-07-22, Nr. P-15-47/3

 

EudraCT Nr.: 2015-000972-88

Merck Sharp & Dohme

 

 

Prostate Cancer Eligible for 1st Line Chemotherapy

A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

Interventional

2015-04-24

P-15-20/2

 

EudraCT Nr.:

2012-002814-38 / IND 015255

Sotio a.s.

Advanced Recurrent Ovarian Cancer

Phase II, Open‐label, Single‐arm, Multicenter Study to Evaluate Efficacy and

Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer (KEYNOTE ‐100)

Interventional

2016-01-27

Nr. P-16-7/2

 

EudraCT Nr.:

2015-003338-29

Merck Sharp & Dohme

Untreated Pancreatic

Ductal Adenocarcinoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic

Ductal Adenocarcinoma

Interventional

2016-03-18

Nr. P-16-14/3

 

 

EudraCT Nr.:

2015-004068-13

Halozyme Therapeutics

The implementation of biomedical trials is tightly related to national and international projects that are being implemented at the Centre. The projects of HOTC include:

Source of financing

Project

Status

Financial mechanisms of European Economic Area and Norway

LT0040 “Academical clinical studies of oncohaematologic biologic markers and individual treatment”

Implemented

LT0112 „National programme of research of hereditary paediatric cancer”

Implemented

Lietuvos moksl

o taryba

LIG-19/2010 „Molecular markers for prevention, early diagnostics and treatment of breast and ovarian cancer”

Implemented

„Purposeful new sequencing for genetic predisposition of breast, ovarian and colorectal cancer”

Under implementation


Publications:

  1. Vaisvilas M., Buseckaite S., Mickeviciute O., Cekauskiene R., Griskevicius L., Peceliunas V.  High-dose methylprednisolone for the treatment of sinusoidal obstruction syndrome in adults. Bone Marrow Transplantation, Jan 29 (2018). Abstract
  2. Bukauskas A., Griskevicius L., Peceliunas V. Lessons Learned from early experiences with vedolizumab for steroid-refractory acute graft- versus-host disease with gastrointestinal involvement. Biol Blood Marrow Transplant, Sep (2017). Abstract
  3. Giles F.J., ... , Griskevicius L., et. al., Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. Aug (2017)  Abstract
  4. Beisa A., ..., Griskevicius L., et. al., The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Langenbecks Arch Surg, Mar (2017) Abstract
  5. Toft N., ... , Griskevicius L.,  et al., Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia. Leukemia, Aug 18 (2017). Abstract
  6. Dirse V., Norvilas R., Gineikiene E., Matuzevičienė R., Griskevicius L., Preiksaitiene E., ETV6 and NOTCH1 germline variants in adult acute leukemia. Leukemia & Lymphoma,  Aug 4 (2017). Abstract
  7. Stegmayr B, ... , Griskevicius A., Audzijoniene J., et al., Distribution of indications and procedures within the framework of centers participating in the WAA apheresis registry. Transfusion and Apheresis Science, Feb, 56(1):71-74 (2017). Abstract
  8. Valatkaite-Rakstiene B. ,  Cekauskiene R., Griskevicius L., Jakubauskas  A., Identification of a novel HLA-B*13 allele, HLA-B*13:99, by sequence-based typing in German bone marrow donor. HLA, Feb 5 (2017). Abstract
  9. Beisa A., Kvietkauskas M., Beisa V., Stoskus M., Ostaneviciute E., Jasiunas E., Griskevicius L., Strupas K., The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Langenbecks Arch Surg, Feb 03 (2017). Abstract
  10. Hoffmann V.S., ... , Griskevicius L., et al., Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia, Aug 29 ( 2016). Abstract
  11. Jewell R.C, Kipps T.J., Dürig J., Griskevicius L., Stilgenbauer S., Smolej L., Mayer J., Hess G., Hernandez-Ilizaliturri F.J., Padmanabhan-Iyer S., Fang L., Goldstein N., Gorczyca M., Gupta I., Lisby S., Wierda W.G.; Hx-CD20-407 Study Investigators. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leukemia & Lymphoma, Jul 7:1-9 (2016). Abstract.
  12. Brand B., Gruppo R., Wynn T.T., Griskevicius L., Lopez Fernandez M.F., Chapman M., Dvorak T., Pavlova B.G., Abbuehl B.E. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients. Haemophilia, Jul 22(4):e251-8 (2016). Abstract.
  13. Rimsevicius L., Bagarauskyte R., Griskevicius A., Audzijoniene J., Griskevicius L., Miglinas M. Successful adsorption of anti-A/B antibodies with multiple personal use columns in AB0 incompatible kidney recipients: A single centre experience. Journal of Clinical Apheresis, Jun 22 (2016). Abstract.
  14. Stoskus M, Eidukaite A, Griskevicius L. Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells. Leukemia Research, Aug, 47:16-21 (2016). Abstract.
  15. Dirse V., Gineikiene E., Zvirblis T., Bertasiute R., Paulssonc K., Griskevicius L. Single nucleotide polymorphism array analysis of clonal evolution in younger adult acute lymphoblastic leukemia. Leukemia & Lymphoma, Mar 21:1-4 (2016). Abstract.
  16. Beinortas T., Tavoriene I., Zvirblis T., Gerbutavicius R., Jurgutis M., Griskevicius L. Chronic myeloid leukemia icidence, survival and accesibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013. BMC Cancer, 16(1):198 (2016). Abstract.
  17. Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K., The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynologia Polska, 67 (1): 35–40. (2016). Abstract.
  18. Stoskus M, Vaitkeviciene G, Eidukaite A, Griskevicius L., ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia. Blood Cells , Molecules and Diseases, 57:30-34. (2016). Abstract.
  19. Mörtzell Henriksson M, ...., Griskevicius A. et al. Adverse events in apheresis: An update of the WAA registry data. Transfusion and Apheresis Science. (2016). Abstract.
  20. Hochhaus A, ... , Griskevicius L. et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. Jan; 30(1):57-64. (2016). Abstract.
  21. Dirse V., Bertasiute A, Gineikiene E, Zvirblis T, Dambrauskiene R, Gerbutavicius R, Juozaityte E, Malciute L, Paulsson K, Griskevicius L. : A population-based single nucleotide polymorphism array analysis of genomic aberrations in younger adult acute lymphoblastic leukemia patients. Genes Chromosomes Cancer. May; 54(5):326-33. (2015). Abstract.
  22. Blanco I, ... , Janavicius R et al., Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 MutationPLoS One. Apr 1; 10(4):e0120020 (2015). Abstract.
  23. Peterlongo P, , ... , Janavicius R et al., Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutationCancer Epidemiol Biomarkers Prev. Jan; 24(1):308-16 (2015).Abstract.
  24. Giedraitienė N., ..., Griškevičius L. et al. Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-betaMed Sci Monit. 21:1512-9 (2015). Abstract.
  25. Maliukevičiūtė, I., ..., Griškevičius, A. et al. AB0 nesuderinamumas neturi įtakos ankstyvam inkstų transplanto funkcionavimui po gyvų donorų organų transplantacijos. Medicinos teorija ir praktika, 21:231-234 (2015).
  26. Toft, N., ..., Griskevicius, L. et al. Toxicity profile and treatment delays in NOPHO ALL2008 - comparing adults and children with Philadelphia chromosome-negative acute lymphoblasticEur J Haematol, (2015). Abstract.
  27. Rebbeck, T.R., ..., Janavicius, R. et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarianJAMA, 313:1347-61 (2015). Abstract.
  28. Hoffman, V.S., ..., Griskevicius, L. et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 EuropeanLeukemia, 29:1336–1343 (2015).Abstract.
  29. Kuchenbaecker, K.B., ..., Janavicius, R. et al. Identification of six new susceptibility loci for invasive epithelial ovarianNature Genetics, 47:164-171 (2015). Abstract.
  30. White, H., ..., Gineikiene, E. et al. A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR. Leukemia, 29:369-376 (2015). Abstract.
  31. Buser L., Bihl M., Rufle A., Mickys U., Tavoriene I., Griskevicius L., Tzankov A. Unique Composite Hematolymphoid Tumor Consisting of a Pro-T Lymphoblastic Lymphoma and an Indeterminate Dendritic Cell Tumor: Evidence for Divergent Common Progenitor CellPathobiology, 81:199-205 (2014). Abstract.
  32. Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L., Comprehensive BRCA1 and BRCA2 mutational profile inCancer Genet. May; 207(5):195-205 (2014).  Abstract.
  33. Osorio A , ... , Janavicius R et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. Apr 3; 10(4):e1004256 (2014). Abstract.
  34. Dymerska D , ... , Janavicius R et al. Lynch syndrome mutations shared by the Baltic States and Poland.Clin Genet. Aug; 86(2):190-3 (2014).
  35. Dirse V., Burnyte B., Gineikiene E., Griskevicius L. and Utkus A. 2014 A novel de novo 2.5 Mb microdeletion of 7q22.1 harbours candidate gene for neurobehavioural disorders and mental retardation. Journal of Genetics, 93 (2014).
  36. Rascon, L. Rageliene, S. Stankeviciene, D. Palionis, A.E. Tamosiunas, N. Valeviciene, T. Zvirblis, An assessment of iron overload in children treated for cancer and nonmalignant hematologic disorders. Eur J Pediatr (2014).  Abstract.
  37. Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer. Int J Gynecol Cancer, 24(8):1395-400 (2014).  Abstract.
  38. Samalavicius R., Serpytis M., Ringaitiene D., Grazulyte D., Bertasiute R., Rimkus B., Matulionyte R., Ambrazaitiene R., Sipylaite J., Kacergius T., Griskevicius L. Successful use of extracorporeal membrane oxygenation in a human immunodeficiency virus infected patient with severe acute respiratory distress sindrome. AIDS Research and Therapy, 11(37):1-6 (2014).  Abstract.
  39. G. Vaitkevičienė, R. Matuzevičienė, M. Stoškus, T. Zvirblis, L. Ragelienė, K. Schmiegelow, Cure rates of childhood acute lymphoblastic leukemia in Lithuania and the benefit of joining international treatment protocol. Medicina, 50(1):28-36 (2014). Abstract.
  40. Guitard J, Degulys A, Buot G, Aline-Fardin A, Dannaoui E, Rio B, Marie JP, Lapusan S, Hennequin C, Acremonium sclerotigenum-Acremonium egyptiacum: a multi-resistant fungal pathogen complicating the course of aplastic anaemia. Clinical Microbiology and Infection, 20(1):O30-O32 (2014).  Abstract.
  41. Frandsen T L, Heyman M, Abrahamsson J, Vettenranta K, Asberg A, Vaitkeviciene G, Pruunsild K, Toft N, Birgens H, Hallbook H, Quist-Paulsen P, Griskevicius L, Helt L, Vilsbol Hansen B, Schmiegelow Kjeld, Complying with the European Clinical Trials directive while surviving the administrative pressure – An alternative approach to toxicity registration in a cancer trial. European Journal of Cancer, 50: 251-259 (2014). Abstract .
  42. Jakubauskas A, Valatkaite B, Griskevicius L, Identification of a novel HLA-B allele, B*56:43, by sequence-based typing in Lithuania bone marrow donor. Tissue Antigens, 83: 52-64 (2014).
  43. Stegmayr B, Ptak J, Nillson T, Berlin G, Mirea V, Axelsson C G, Griskevicius A, Centoni P, Liumbruno G, Audzijoniene J, Mokvist K, Lassen E, Knutson F, Norda R, Mortzell M, Prophet H, Ramlow W, Blaha M, Witt V, Efvergren M, Tomaz J, Newman E, Eloot S, Dhondt A, Lalic K, Sikole A, Derfler K, Hrdlickova R, Tomsova H, Gasova Z, Bhuiyan-Ludvikova Z, Ramsauer B, Vrielink H, Panorama of adverse events during cytapheresis. Transfusion and apheresis science, 48: 155-156 (2013).
  44. Couch FJ, , Janavicius R et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet.; 9(3):e1003212. (2013). Abstract.
  45. Griskevicius A, Audzijoniene J, Griskevicius L, Petrulioniene Z, Laucevicius A, The lipoproteins selections aphereses with LDL Lipopak 400. Transfusion and Apheresis Science, 48: 183 (2013).
  46. Jakubauskas A, Valatkaite B, Griskevicius L, Two novel HLA class II alleles, DRB1*11:31 and DQB1*05:01:05, identified by sequence-based typing. Tissue antigens, 82: 293-300 (2013).
  47. Vaitkeviciene G, Heyman M, Jonsson OG, Lausen B, Harila-Saari A, Stenmarker M, Taskinen M, Zvirblis T, Asberg A, Groth-Pedersen L, Rageliene L, Schmiegelow K, Early morbidity and mortality in childhood acute lymphoblastic leukemija with very high white blood cell count. Leukemia, 1-4 (2013).
  48. Janavicius R, Rudaitis V, Feng B J, Ozolina S, Griskevicius L, Galdgar D, Tihomirova L, Haplotype analysis and ancient origin of the BRCA1 c.41035delA Baltic founder mutation. European Journal of Medical Genetics, 56(3): 125-130 (2013).  Abstract.
  49. Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Asberg A, Schmiegelow K,Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. European Journal of Haematology, 90(5): 404-412 (2013).Abstract .
  50. Gineikiene E, Seinin D, Brasiuniene B, Brazaitis A, Griskevicius L, Jakubauskas A, Clear cell sarcoma expressing a novel chimerical transcript EWSR1 exon 7/ATF1 exon 6. Virchows Archiv, 461(3): 339-343 (2012). Abstract.
  51. Cortes JE, Kim DW, Kantarjian HMBrümmendorf THDyagil IGriskevicius LMalhotra H, Powell C,Gogat K, Countouriotis AM, Gambacorti-Passerini C, Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial, J Clin Oncol (2012).Abstract.
  52. A.L. Petzer, D. Fong, T. Lion, I. Dyagil, Z. Masliak, A. Bogdanovic, L. Griskevicius, S. Lejniece, S. Goranov, L. Gercheva, A. Stojanovic, D. Peytchev, N. Tzvetkov, R. Griniute, A. Stanchev, T. Grubinger, M. Kwakkelstein, P. Schuld, G. Gastl, D. Wolf, High dose imatinib induction followed by standard dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomised multicentre phase III trial. Haematologica, 97: 1562-1569 (2012).  Abstract.
  53. Couch FJ, ..., Janavicius R et al., Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev., 21(4):645-57 2012.Abstract .
  54. Ramus SJ, ..., Janaviciu R et al., Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Hum Mutat., 33(4):690-702 (2012).Abstract .
  55. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, T. Zvirblis, L. Griskevicius, Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk. Lymphoma, 53:641–647 (2012). Abstract.
  56. Ding YC,..., Janavicius R et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. Aug; 21(8):1362-70 (2012).  Abstract.
  57. Janavicius R, Elsakov P. Novel germline MSH2 mutation in lynch syndrome patient surviving multiple cancers. Hered Cancer Clin Pract., 10(1):1 (2012). Abstract.
  58. Mavaddat N, ..., Janaviciu R et al., Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev., 21(1):134-47 (2012). Abstract.
  59. Antoniou AC, ..., Janavicius R et al., Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 15, 20(16):3304-21 (2011). Abstract.
  60. Martrat G,..., Janavicius R et al. Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res. Apr 5; 13(2):R40. (2011).  Abstract.
  61. Ramus SJ,..., Janavicius R et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. Jan 19; 103(2):105-16. (2011).  Abstract.
  62. Mulligan AM, ..., Janavicius R et al., Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res., 13(6):R110 (2011). Abstract.
  63. W.G. Wierda, T.J. Kipps, J. Durig, L. Griskevicius, S. Stilgenbauer, J. Mayer, L. Smolej, G. Hess, R. Griniute, F.J. Hernandez-Ilizaliturri, S. Padmanabhan, M. Gorczyca, C.N. Chang, G. Chan, I. Gupta, T.G. Nielsen, C.A. Russell, Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood, 117:6450–6458 (2011).Abstract .
  64. M. Stoskus, E. Gineikiene, V. Valceckiene, B. Valatkaite, R. Pileckyte, L. Griskevicius, Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities. Blood Cells Mol. Dis., 46:321–326 (2011).  Abstract.
  65. R. Pileckyte, M. Jurgutis, V. Valceckiene, M. Stoskus, E. Gineikiene, J. Sejoniene, A. Degulys, T. Zvirblis, L. Griskevicius, Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk. Lymphoma, 52:1055–1065 (2011).  Abstract.
  66. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, L. Griskevicius, Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin. Cytom., 80B(5):318–323 (2011).Abstract.
  67. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, L. Griskevicius, Flow cytometric detection of immunophenotypically normal plasma cells in multiple myeloma patients provides clinically important information. Laboratorinė medicina, 13(2):59-64 (2011).
  68. R. Janavicius, K. Andrekute, U. Mickys, V. Rudaitis, B. Brasiuniene, L. Griskevicius, Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation. Breast J., 17:409–415 (2011).Abstract .
  69. A. Jakubauskas, R. Vilkeviciene, D. Juskevicius, L. Griskevicius, Identification of a novel HLA-B allele, B*56:31, by sequence-based typing in a Lithuanian individual. Tissue Antigens, 77:262–263 (2011). Abstract.
  70. A. Jakubauskas, V. Valceckiene, K. Andrekute, D. Seinin, A. Kanopka, L. Griskevicius, Discovery of two novel EWSR1/ATF1 transcripts in four chimerical transcripts-expressing clear cell sarcoma and their quantitative evaluation. Exp. Mol. Pathol., 90:194–200 (2011). Abstract.
  71. A. Jakubauskas, D. Juskevicius, L. Griskevicius, C*07:185, a novel HLA-C*07 allele identified by sequence-based typing. Tissue Antigens, 78:155–156 (2011).
  72. A. Jakubauskas, L. Griskevicius, Sequence-based typing showed a novel HLA-DQB1*05 allele, DQB1*05:01:03. Tissue Antigens, 77:157–158 (2011).
  73. V. Valceckiene, R. Kontenyte, A. Jakubauskas, L. Griskevicius, Selection of reference genes for quantitative polymerase chain reaction studies in purified B cells from B cell chronic lymphocytic leukaemia patients. Br. J. Haematol., 151:232–238 (2010). Abstract.
  74. A.L. Petzer, D. Wolf, D. Fong, T. Lion, I. Dyagil, Z. Masliak, A. Bogdanovic, L. Griskevicius, S. Lejniece, S. Goranov, L. Gercheva, A. Stojanovic, D. Peytchev, N. Tzvetkov, R. Griniute, R. Oucheva, H. Ulmer, M. Kwakkelstein, F. Rancati, G. Gastl, High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. Haematologica, 95:908–913 (2010).Abstract .
  75. M. Janeliūnienė, R. Matuzevičienė, L. Griškevičius, Z.A. Kučinskienė. Monitoring of T-cell Acute Lymphoblastic Leukemia by Flow Cytometry. Central Europeen Journal of Medicine, 5(6):651-658 (2010). Publikacijos santrauka.
  76. Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA Journal. Sep; 1(3):397-412 (2010).  Abstract.
  77. R. Janavicius, D. Matiukaite, A. Jakubauskas, L. Griskevicius, Microsatellite instability detection by high-resolution melting analysis. Clin. Chem., 56:1750–1757 (2010).Abstract .
  78. A. Jakubauskas, L. Griskevicius, Haplotype-specific sequencing reveals a novel HLA-A*03 allele, A*030114. Tissue Antigens, 76:71–75 (2010).
  79. A. Jakubauskas, L. Griskevicius, KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay. Arch. Pathol. Lab. Med., 134:620–624 (2010). Abstract.
  80. R. Janavicius, R. Adomaitis, F. Jankevicius, L. Griskevicius, Extremely low risk of pheochromocytomas in complete VHL gene deletion cases. Hum. Mutat., 30:1365–1366; author reply 7 (2009). Abstract.
  81. L. Griskevicius, R. Stulpinas, I. Vengalyte, S. Saulyte-Trakymiene, U. Mickys, D. Pranys, J. Kurtinaitis, M. Jurgutis, Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia. Leuk. Res., 33:587–588 (2009). Abstract.
  82. E. Gineikiene, M. Stoskus, L. Griskevicius, Single nucleotide polymorphism-based system improves the applicability of quantitative PCR for chimerism monitoring. J. Mol. Diagn., 11:66–74 (2009).Abstract .
  83. Janavicius R, Pepalyte I, Kucinskas V. Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania. Breast Cancer Res Treat. Sep; 117(2):467-9. (2009).
  84. E. Gineikiene, M. Stoskus, L. Griskevicius, Recent advances in quantitative chimerism analysis. Expert Rev. Mol. Diagn., 9:817–832 (2009). Abstract.
  85. A. Engert, L. Griskevicius, Y. Zyuzgin, H. Lubenau, A. del Giglio, XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk. Lymphoma, 50:374–379 (2009).Abstract .
  86. M. Balciunas, L. Bagdonaite, R. Samalavicius, L. Griskevicius, A. Vuylsteke, Pre-operative high sensitive C-reactive protein predicts cardiovascular events after coronary artery bypass grafting surgery: a prospective observational study. Ann. Card. Anaesth., 12:127–132 (2009). Abstract.
  87. M. Balciunas, L. Bagdonaite, R. Samalavicius, L. Griskevicius, Evaluation of the impact of coronary artery bypass grafting surgery on soluble markers of endothelial activation, vascular and intercellular adhesion molecules. Seminars in Cardiovascular medicine, 15(1):4 (2009).
  88. J. Korsakas, K. Andrekute-Aleksiejiene, A. Bukauskas, B. Brasiuniene, F. Jankevicius, L. Griskevicius, Sequential high-dose chemotherapy with hematopoietic stem-cell support in poor risk, relapsed or refractory germ-cell tumor patient treatment: Lithuanian experience. European Urology Supplements, 8(8):600-601 (2009).
  89. Jakubauskas A, Kriukiene E, Trinkunaite L, Sapranauskas R, Jurenaite-Urbanaviciene S, Lubys A. Bioinformatic and partial functional analysis of pEspA and pEspB, two plasmids from Exiguobacterium arabatum sp. nov. RFL1109. Plasmid, 61:52-64 (2009). Abstract .
  90. N.R. Valevičienė, E. Sadauskienė, Z. Petrulionienė, M. Matačiūnas, D. Zakaraitė, A. Tamošiūnas, L. Griškevičius, S. Glaveckaitė, A. Laucevičius, Diagnosis, treatment and subsequent remission of a rare tumor – primary cardiac lymphoma. Seminars in Cardiovascular Medicine, 14(5):1-6 (2008).
  91. R. Kviliute, A. Paskevicius, J. Gulbinovic, R. Stulpinas, L. Griskevicius, Nonfatal Trichoderma citrinoviride pneumonia in an acute myeloid leukemia patient. Ann. Hematol., 87:501–502 (2008).
  92. Jakubauskas A, Sasnauskas G, Giedriene J, Janulaitis A. Domain organization and functional analysis of Type IIS restriction endonuclease Eco31I. Biochemistry47:8546-8556 (2008). Abstract .
  93. M. Balciunas, L. Bagdonaite, A. Baublys, L. Griskevicius L, Impact of perioperative endothelial function on cardiovascular complications after on pump coronary artery bypass grafting surgery. Laboratorine medicina, 9(4):180-185 (2007).
  94. J. Priluckiene, I. Kriukelyte, M. Jurgutis, I. Trociukas, [Chronic graft-versus-host disease presenting as nephrotic syndrome after allogenic hematopoietic stem cell transplantation]. Medicina (Kaunas) 43 Suppl 1:148–152 (2007).Abstract .
  95. U. Dumpis, J. Gulbinovic, J. Struwe, A. Lagergren, L. Griskevicius, U. Bergman, Differences in antibiotic prescribing in three university hospitals in the Baltic region revealed by a simple protocol for quality assessment of therapeutic indications. Int. J. Clin. Pharmacol. Ther., 45:568–576 (2007).Abstract.
  96. Jakubauskas A, Giedriene J, Bujnicki JM, Janulaitis A. Identification of a single HNH active site in Type IIS restriction endonuclease Eco31I. Journal of Molecular Biology, 370:157-169 (2007).  Abstract.
  97. H. Xie, L. Griskevicius, L. Stahle, Z. Hassan, U. Yasar, A. Rane, U. Broberg, E. Kimby, M. Hassan, Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci., 27:54–61 (2006). Abstract.
  98. F. Sjoo, Z. Hassan, M. Abedi-Valugerdi, L. Griskevicius, C. Nilsson, M. Remberger, J. Aschan, H. Concha, U. Gaughan, M. Hassan, Myeloablative and immunosuppressive properties of treosulfan in mice. Exp. Hematol., 34:115–121 (2006).Abstract .
  99. Tamulaitiene G, Jakubauskas A, Urbanke C, Huber R, Grazulis S, Siksnys V. The crystal structure of the rare-cutting restriction enzyme SdaI reveals unexpected domain architecture. Structure, 14: 1389-1400 (2006). Abstract .
  100. Azarinskas A, Maneliene Z, Jakubauskas A. Hin4II, a novel prototype restriction endonuclease from Haemophilus influenzae RFL4: discovery, cloning and expression in Escherichia coli. Journal of Biotechnology, 123: 288-296 (2006).  Abstract.
  101. Eidukevicius R, Characiejus D, Janavicius R, Kazlauskaite N, Pasukoniene V, Mauricas M, Den Otter W.: A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample. BMC Cancer. Sep 22; 5:122 (2005). Abstract .
  102. Tiemann B, Depping R, Gineikiene E, Kaliniene L, Nivinskas R, Rüger W. ModA and ModB, two ADP-ribosyltransferases encoded by bacteriophage T4: catalytic properties and mutation analysis. J Bacteriol. 2004 Nov; 186(21):7262-72.  Abstract.
  103. H.J. Xie, U. Yasar, S. Lundgren, L. Griskevicius, Y. Terelius, M. Hassan, A. Rane, Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J., 3:53–61 (2003).  Abstract.
  104. H.J. Xie, U. Broberg, L. Griskevicius, S. Lundgren, S. Carlens, L. Meurling, C. Paul, A. Rane, M. Hassan, Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant., 31:197–203 (2003).Abstract .
  105. L. Griskevicius, U. Yasar, M. Sandberg, M. Hidestrand, E. Eliasson, G. Tybring, M. Hassan, M.L. Dahl, Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur. J. Clin. Pharmacol., 59:103–109 (2003).Abstract .
  106. L. Griskevicius, L. Meurling, M. Hassan, Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma. Ther. Drug Monit., 24:405–409 (2002).Abstract .
  107. Bitinaite J, Mitkaite G, Dauksaite V, Jakubauskas A, Timinskas A, Vaisvila R, Lubys A, Janulaitis A. Evolutionary relationship of Alw26I, Eco31I and Esp3I, restriction endonucleases that recognise overlapping sequences. Molecular Genetics and Genomics267:664-672 (2002).  Abstract.
  108. L. Griskevicius, J. Gulbinovic, I. Trociukas, et al., Neprognozuojama ciclofosfomido ir 4-hidroksiciclofosfomido farmokokinetika vartojant įprastinę ciclofosfomido dozę. Laboratorinė medicina, 4:21-28 (2001).
  109. Sommer N, Salniene V, Gineikiene E, Nivinskas R, Rüger W. T4 early promoter strength probed in vivo with unribosylated and ADP-ribosylated Escherichia coli RNA polymerase: a mutation analysis.Microbiology. 2000 Oct; 146(Pt 10):2643-53.  Abstract.
  110. J. Dadonienė, I. Trociukas, V. Gražienė, Z. Mackevičius, Idiopathic Hypereosinophilic Syndrome on the Border with Churg-Sraus Vasculitis. ISSN 1292-Acta medicina Lithuanica, 6(2):135-137 (1999).
  111. J. Balsys, V.A. Bumelis, I. Gircontaitė, M. Leckienė, M. Mauricas, I. Trociuk, Total and monoclonal immunoglobulin detection and qantification in human sera by enzyme-liked immunosorbent assay., ISSN 1392 –Biology, N3, 65 – 72 (1994).
  112. Nivinskas R, Malys N, Klausa V, Vaiskunaite R, Gineikiene E. Post-transcriptional control of bacteriophage T4 gene 25 expression: mRNA secondary structure that enhances translational initiation. J Mol Biol. 1999 May 7; 288(3):291-304. Abstract .
  113. Gircontaitė, M. Leckienė, I. Trociuk, V. Giedraitis, M. Mauricas, A rapid ELISA test for detection of human paraproteins. Eur J Clin Chem Clin Biochem, 34:349-353 (1996).Abstract .

Presentations delivered at international conferences:

  1. Bukauskas A., Stoskus M., Valceckiene V., Rucinskaite G., Mickeviciute O., Slobinas A., Jucaitiene R., Slepikiene I, Peceliunas V., Trociukas I., Griskevicius L., Mesenchymal stromal cells in patients with steroid-refractory III-IV grade acute graft versus host disease after allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusion. EBMT Conference, Lisbon, Portugal (2018)
  2. Bukauskas A., Stoskus M., Valceckiene V., Griskevicius L., Small scale production of clinical grade MSCS for a single center setting. EBMT Conference, Lisbon, Portugal (2018)
  3. Rucinskaite G., Cekauskiene R., Mickeviciute O., Trociukas I., Griskevicius L., Peceliunas V. EBMT risk score impact on mortality rate for allogeneic hematopoietic stem cell transplantation.EBMT Conference, Lisbon, Portugal (2018)
  4. Jakubauskas A., Cekauskiene R. Griskevicius L. Impact of anti-HLA antibodies on early complications and outcome after unrelated donor haematopoietics stem cell transplantation (HSCT). EBMT Conference, Lisbon, Portugal (2018)
  5. Vicent Claramunta A., Paskevicius A. , Svediene J. , Gudeliunaite E., Kiveryte S., Petrauskaite R., Griskevicius L., Zolumskis A., Naujalis E. Thermal Desorption Methodology for Volatile Organic Compounds (VOCs) Identification: Possible Application in Invasive Fungal Infections. Summer school for Metrology: Metrology for Quality of Life. Italy (2016).
  6. Bukauskas A, Valceckiene V., Stoskus M, Jureviciute V, Bertasiute R, Peceliunas V., Slobinas A., Trociukas I., Griskevičius L. Mesenchymal stromal cells in patients with steroid-refractory III-IV grade Acute Graft versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation or Donor Lymphocyte Infusion. EBMT Conference, Valencia (2016)
  7. Valceckiene V., Stoskus M., Bukauskas A, Griskevicius L. Towards a more economical large-scale production of clinical grade MSCs. EBMT Conference, Valencia (2016)
  8. Cekauskiene R., B. Valatkaite B., Griskevicius L., Jakubauskas A. Relevance of anti-HLA antibodies in unrelated donor allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl 2016; EBMT Conference, Valencia (2016)
  9. R. Cekauskiene. Extracorporeal photopheresis in GvHD treatment, Vilnius University BMT dpt. Experience. 9th Baltic Conference of hematology, April 24-26, Vilnius (2014)
  10. R. Cekauskiene. Lithuanian Bone Marrow Donor Registry - 10 years of experience. 9th Baltic Conference of hematology, April 24-26, Vilnius (2014)
  11. A Beiša, V Beiša, E Ostanevičiūtė, M Stoškus, D Juškevičius, D Petroška, L Griškevičius, K Strupas, BRAF V600E-opportunity to decrease the amount of thyroid surgery. Langenbeck‘s Archive of Surgery. 5th ESES Workshop-Surgery of Thyroid Cancer, vol. 398, p. 759-788 (2013).
  12. V. Peceliunas, BM and PB plasma cell subpopulation analysis by multicolor flow cytometry. Nordic Stem Cell treatment, Scientific Meeting. November 26th, Oslo (2012).
  13. L. Kryzauskaite, L. Deberdt, L. Rouse, R. Goodrich, Mirasol® PRT Treated Platelet Products in Autologous Stem Cell Transplant Patients. Transfusion, 51, Suppl. s3, pp. 37A–38A (2011). 
  14. R. Pileckyte, High Dose Methylprednisolone (HDMP) and Rituximab (RTX) are Effective in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) with High Genetic Risk. Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 19 (2010)
  15. M. Stoskus, Expression Analysis of IMP Family Isoforms in Acute and Chronic Leukemia Reveals a Unique Profile of ETV6/RUNX1 Entity and Highlights Potential IMO Profiling Utility in Other B Lineage Neoplasms. Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 20 (2010)

Presentations published at international conferences:

  1. Dapkeviciute A., Griskevicius L., Sapoka V., Martynova E., Peceliunas V.  Time from symptom onset to diagnosis and treatment among hematological malignancies: disease, patient and health system related influencing factors. Abstract book of 23nd Congress of the European Hematology Association, Stockholm, Sweden, June 14-17 (2018).
  2. Utke Rank C.,  …, Griskevicius L., et al., Thromboembolism in ALL Patients 1-45 Years Treated According to the NOPHO-ALL 2008 Protocol.  Abstract book of  59th ASH annual meeting, Atlanta, December 9-12 (2017)
  3. Dirse V., Drachneris J., Mickys U., Stoskus M., Griskevicius L. Genomic prifiling of BCL2 and MYC double expressior diffuse large B cell lymphoma.  Abstract book of 22nd Congress of the European Hematology Association, Madrid, June 22-25 (2017).
  4. Norvilas R., Dirse V., Gineikiene E., Mickeviciute O., Pakstyte S., Stoskus M., Griskevicius L.Association analysis of cytogenetic and genetic and genetic alterations in primary myelofibrosis. Abstract book of 22nd Congress of the European Hematology Association, Madrid, June 22-25 (2017).
  5. Beisa A, Kvietkauskas M, Beisa V, Stoskus M, Ostaneviciute E, Griskevičius L, Strupas K. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Poster presentation at 7th Symposium of European society of endocrine surgery (ESES). Oxford, UK (2017).
  6. Pileckyte R., Klimiene I., Valceckiene V., Sejoniene J., Viselgaite L., Zvirblis T., Griskevicius L. Rituximab in addition to methylprednisolone in pretreated elderly or unfit patients with B chronic lymphocytic leukemia. Poster Presentation at the XVI International Workshop on Chronic Lymphocytic Leukaemia, September 7-9, Sydney (2015)
  7. Brand, B., ..., Griskevicius, L. et al. Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures. Abstract of 57th ASH Annual Meeting and Exposition, December 5-8, Orlando, Florida (2015).
  8. Atkinson, V., ..., Tulyte, S. et al. Safety and Effectiveness Analysis of V600 BRAF-Mutated Metastatic Melanoma Patients From the Dabrafenib Plus Trametinib Named Patient Program – DESCRIBE II Study. Poster Presentation at the 18th ECC – 40th ESMO European Cancer Congress, Vienna, Austria, 25-29 September (2015).
  9. Brand, B., ..., Griskevicius, L. et al. Initial results of a clinical trial evaluating a full-lenght pegylated recombinant factor VIII with extended half-life for the perioperative control of hemostasis in hemophilia A. Abstract of Congress of the International Society on Thrombosis and Hemostasis, Toronto, June 20-25, (2015). 
  10. Ivaskevicius, V., Goldmann, G., Kryzauskaite, L., Rutkauskiene, G., Horneff, S., Marquardt, N., Pavlova, A., Oldenburg, J. Congenital FXI Deficiency: A Report of Nine Families From Germany And Lithuania.Abstract of Congress of the International Society on Thrombosis and Hemostasis, Toronto, June 20-25, (2015).
  11. Hellman, A., ..., Griskevicius, L. et al. : Efficacy and Safety of Frontline Nilotinib in 1089 European Patients With CML-CP: ENEST1st Final Analysis. Abstract of European Hematology Association 20th Congress,Vienna, June 11-14, (2015).
  12. Beisa, L., ..., Griskevicius, L. et al. The potential utility of BRAF V600E status follow-up in FNA of thyroid nodules. Hyperparathyroidism due multiple glanda disease: an evidence-based perspective, Varna, Bulgaria, May 28-30, (2015).
  13. Cekauskiene, R., Extracorporeal Photopheresis and Rituximab for the Treatment of Steroid Refractory Graft versus Host Disease. EBMT Conference, Milan (2014)
  14. M Stoskus, A Eidukaite, L Griskevicius, ETV6/RUNX1 transcript is a potential target of RNA-binding protein IGF2BP1. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 6 (2013).
  15. V Dirse, T Zvirblis, L Griskevicius, SNP array analysis of adult ALL: a population based study of lithuanian patients. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 7 (2013).
  16. R Pileckyte, T Zvirblis, V Ivanauskaite, I Klimiene, L Griskevicius, Chronic lymphocytic leukemia (CLL): epidemiology, comorbidities and treatment preference in daily clinical practice. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 546 (2013).
  17. V Peceliunas, A Bertasiute, T Zvirblis, L Griskevicius, Second autologous transplantation for patients with relapsed multiple myeloma. Abstract book of 18th Congress of the European Hematology Association,Stockholm, June 13-16, p. 608 (2013).
  18. R Stulpinas, J Drachneris, A Simbelyte, L Griskevicius, U Mickys, Fulicullar lymphoma in situ: serious of 8 cases. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 647 (2013).
  19. Cekauskiene. Mononuclear cell collection for Extracorporeal photopheresis in Graft versus host disease patients: a comparison of Cobe Spectra and Spectra Optia devices. EBMT Conference, July 7-10, London (2013)
  20. G. Barosi, M. B. Agarwal, S. Zweegman, W. Willenbacher, S. Pakstyte, R. Raymakers, N. Cantoni, A. Modi, M. Khan, J. R. Perez, H. Hasselbalch, J. P. V. Viveros, C. Linardi, H.Gisslinger, A. H. D. Gabriel, F. Palandri, D. Lavie, C. Harrison: An individual patient supply program for ruxolitinib for the treatment of patiens with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. 54th ASH Annual Meeting and Exposition, December 8-11, Atlanta, Georgia (2012).
  21. A Hochhaus, G Rosti, P Le Coutre, G Ossenkoppele, L Griskevicius, D Réa, A Hellmann, T Masszi, J Steegmann, FX Mahon, K Porkka, N Cross, M Müller, C Piccolo, P Schuld, A Pellegrino, F Giles, ENEST1ST: Nilotinib in patients with newly diagnosed chrnic myeloid leukemia in chronic phase (CML-CP): a Eauropean and EUTOS clinical initiative for standardization of molecular response. Abstract book of 17thCongress of the European Hematology Association, Amsterdam, June 14-17, p. 74 (2012).
  22. T Zvirblis, V Ivanauskaite, I Tavoriene, R Gerbutavicius, E Juozaityte, L Malciute, M Jurgutis, J Daubariene, D Ramanauskiene, L Rageliene, L Griskevicius, Increasing relative survival in chronic myeloid leukemija (CML): a population-based study in Lithuania. Abstract book of 17th Congress of the European Hematology Association, Amsterdam, June 14-17, p. 312-313 (2012).
  23. R Pileckyte, V Valceckiene, T Zvirblis, L Griskevicius, Dose dense high dose methylprednisolone (HDMP) and rituximab (RTX) are effective in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion (17p del)/TP53 mutation. Abstract book of 17th Congress of the European Hematology Association, Amsterdam, June 525-526, p. 74 (2012).
  24. Miglinas, Marius, Ašakienė, Eglė, Vareikienė, Loreta, Aleknienė, Dalia, Supranavičienė, Lilija, Rimševičius, Laurynas, Želvys, Arūnas, Griškevičius, Antanas, Griškevičius, Laimonas, The first AB0-incompatible kidney transplantation in Lithuania and Baltic States. Abstract book of 10th Baltic Nephrology Conference, Tartu, September 20-22, p. 55 (2012).
  25. Janavičius, Ramūnas, Rudaitis, Vilius, Griškevičius, Laimonas, Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. European journal of human genetics : European human genetics conference, Nurnberg, June 23-26, p. 161 (2012).
  26. Daunoravičius, Dainius, Jakubauskas, Artūras, Griškevičius, Laimonas, Čibiras, Sigitas Vladas, Žurauskas, Edvardas, Maneikienė, Vytė Valerija, Čelutkienė, Jelena, Ručinskas, Kęstutis, Jasulaitis, Algimantas, Grabauskienė, Virginija, Inflammatory cardiomyopathy: aetiopathogenetic markers for diagnosis of disease subentities and for aetiology directed treatment. Abstract book of Heart Failure Congress,Belgrade, May 19-22 (2012).
  27. D. Palionis, A. Tamosiunas, J. Rascon, L. Rageliene, S. Stankeviciene, T. Zvirblis, Assessment of Trsnfusion Related Cardiac and Liver Iron Overload in Child Patients with MRI T2* Technique: Single Center Initial Experience, ELN Frontier Meeting 2012, Istanbul, Turkey, November 9-11, p. 33 (2012).
  28. R. Cekauskiene. Lithuanian Bone Marrow Donor Registry: experience of 2004-2011. Practical Aspects of Donor-Recipient Matching, HSCT Conference, December 17-18, Wroclaw (2012)
  29. R. Cekauskiene, L. Kryzauskaite, A. Griskevicius, K. Sinkevic, R. Matuzeviciene, T. Zvirblis, I. Trociukas, L. Griskevicius, Extracorporeal photopheresis (ECP) and rituximab (RTX) for the treatment of steroid refractory graft versus host disease (SR-GVHD). Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 179 (2011).
  30. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, T. Zvirblis, L. Griskevicius, Circulating plasma cells (CPCS) predict the outcome of relapsed or refractory multiple myeloma (RR MM). Abstract book of 16thCongress of the European Hematology Association, London, June 9–12, p. 369–370 (2011).
  31. T. Zvirblis, I. Vengalyte, R. Pileckyte, D. Pranys, M. Jurgutis, L. Griskevicius, Population based analysis of chemo-immunotherapy in adult Burkitt lymphoma and leukaemia (BLL). Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 399–400 (2011).
  32. J.Hasford, A. Almeida, M. Baccarani, A. Bogdanovic, R. Clark, A. Colita, P. Costeas, E. Demeckova, I. Dyagil, H. Everaus, L. Griskevicius, J. Guilhot, R. Hehlmann, A. Hellmann, V. Hoffmann, K. Indrak, P. Koskenvesa, B. Labar, S. Lejniece, D. Lindoerfer, G. Ossenkoppele, P. Panagiotidis, G. Rosti, B. Simonsson, J. Steegmann, J. Thaler, A. Turkina, D. Zackova, A. Zaritskey, I. Zupan, The European Population-based CML Registry Objectives and First Results. Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 399–400 (2011).
  33. R. Pileckyte, R. Matuzeviciene, A. Janiulioniene, M. Jurgutis, T. Zvirblis, L Griskevicius, T regulatory cells (TREG) in relapsed/refractory chronic lymphocytic leukemia (CLL) treated with high dose methylprednisolone (HDMP) and rituximab. Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 279 (2011).
  34. M. Stoskus, E. Gineikiene, V. Valceckiene, B. Valatkaite, R. Pileckyte, L. Griskevicius, Identification of characteristic IGF2BP expression patterns in B-lineage neoplasms. Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 311 (2011).
  35. A. Macioniene, S. Kiveryte, Z. Kucinskiene, J. Gulbinovic, L. Griskevicius, A. Jakubauskas. Real-time PCR typing of CTX-M and SHV family genes of extended-spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates from Vilnius University Hospital Santariskiu Clinics, Lithuania. 21st ECCMID – 27th ICC, Milan (2011).
  36. R.Cekauskiene. Combined Extracorporeal Photopheresis (ECP) and Rituximab (Rtx) for the Treatment of Steroid Refractory Graft versus Host Disease (SR-GvHD) after Allogeneic Stem Cell Transplantation (alloSCT). ISFA Conference, September 14-17, Vienna (2011)
  37. E. Gineikiene, M. Stoskus, L. Griskevicius, SNP-based system improves the applicability of qPCR for chimerism monitoring. Eur. J. Human Genetics: European Human Genetic Conference 2009, May. 17, Suppl. 2, p. 285 (2009).
  38. R. Cekauskiene, Lithuanian National Bone Marrow Donor Registry (LBMDR) – 6 years of experience.Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 35 (2010).
  39. A. Degulys, R. Pileckyte, E. Gineikiene, V. Valceckiene, M. Stoskus, R. Dambrauskiene, U. Mickys, L. Griskevicius, Bilineage involvement of the fusion gene in a patient with FIP1L1-PDGFRA positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a case report. Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 37 (2010).
  40. A. Degulys, R. Pileckyte, E. Gineikiene, V. Valceckiene, M. Stoskus, R. Dambrauskiene, U. Mickys, L. Griskevicius, Bilineage involvement of the fusion gene in a patient with FIP1L1-PDGFRA positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a case report. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 601 (2010).
  41. R. Pileckyte, N. Gailiute, L. Malciute, A. Drungiene, L. Griskevicius, Repeated administration of low dose monoclonal antiCD20 antibody rituximab (Rtx) in refractory acquired hemophilia A (AHA): a case report.
  42. R . Pileckyte, I. Vengalyte, L. Griskevicius, Rare infections in primary Hodgkin‘s disease.
  43. I. Vengalyte, R. Pileckyte, L. Griskevicius, Aspergillus Galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in hematological patients. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 364 (2010).
  44. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, L. Griskevicius, Circulating plasma cells (CPC) predict the outcome of relapsed or refractory multiple myeloma (RR MM). Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 396 (2010).
  45. R. Pileckyte, M. Jurgutis, V. Valceckiene, M. Stoskus, E. Gineikiene, J. Sejoniene, A. Degulys, A. Jakubauskas, L. Griskevicius, Dose dense high dose methylprednisolone (HDMP) and rituximab (RTX) are effective in relapsed or refractory high risk chronic lymphocytic leukemia (CLL). Abstract book of 15thCongress of the European Hematology Association, Barcelona, June 10–13, p. 325 (2010).
  46. A. Petzer, D. Wolf, D. Fong, T. Lion, I. Dyagil, Z. Masliak, A. Bogdanovic, L. Griskevicius, S. Lejniece, S. Goranov, L. Gercheva, A. Stojanovic, D. Peytchev, N. Tzvetkov, R. Griniute, R. Oucheva, T. Grubinger, M. Kwakkelstein, F. Rancati, G. Gastl, High dose imatinib induction (800 mg/day, 6 months) induces significantly higher cytogenetic and molecular responses in pre-treated chronic phase CML – Phase III CELSG 'ISTAHIT' trial – First results. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 53 (2010).
  47. G. Wierda, T. Kipps, J. Dürig, L. Griskevicius, S. Stilgenbauer, J. Mayer, L. Smolej, G. Hess, R. Griniute, F. Hernandez-Ilizaliturri, S. Padmanabhan, M. Gorczyca, I. Gupta, T. Nielsen, C. Russell,Chemoimmunotherapy with ofatumumab, fludarabine and cyclophosphamide in previously untreated patients with chronic lymphocytic leukemia: A phase II international trial. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, pp. 320–321 (2010).
  48. A. Bukauskas, J. Korskas, K. Andrekute-Aleksiejiene, B. Brasiuniene, I. Trociukas, F. Jankevicius, L. Griskevicius, Sequential high-dose chemotherapy with hematopoietic stem-cell tumor patient treatment: Lithuanian experience. EAU 3rd Norh Eastern European Meeting (NEEM), September 11-12, p. 92 (2009).
  49. L. Griskevicius, A. Slobinas, I. Trociukas, J. Balsys, Early experience with high dose Cytarabine (HD AraC) in the treatment of Acute Leukemia at Vilnius University Hospital Santariskiu Klinikos. Second Baltic States Haematologists Congress, Riga, June 7-9, p. 19 (2000).


Atnaujinta 2018-04-19
Straipsnis parodytas: 5107 kartų(kartus)
 
Reklaminis skydelis
Reklaminis skydelis
Reklaminis skydelis
Reklaminis skydelis

Siekdami pagerinti Jūsų naršymo patirtį lankantis Santa.lt svetainėje, naudojame slapukus (angl. cookies) – tai nedidelės informacijos rinkmenos, kurias jūsų naudojamo įrenginio naršyklė priima iš svetainės kurioje lankotės. Surinkta informacija iš slapukų mums padeda efektyviau nustatyti naršymo įpročius, veiksmus bei nustatymus (pvz., kalbą, šrifto dydį ir kitas rodymo parinktis), o jums nereikia jų kaskart pasirinkti lankantis svetainėje ar naršant įvairiuose jos puslapiuose. Kad interneto svetainė veiktų, nebūtina leisti naudoti šiuos slapukus, bet sutikus su slapukų politika, naršyti jums bus paprasčiau. Išsamesnė informacija suteikiama AllAboutCookies.org. Galite ištrinti visus jau esančius jūsų kompiuteryje slapukus, o dauguma naršyklių nustatytos taip, kad slapukai nebūtų įrašomi jūsų įrenginyje. Su slapukais susijusi informacija nenaudojama jūsų tapatybei nustatyti ar kitais nei pirmiau aprašytais tikslais. Daugiau apie slapukus ir kaip jų atsisakyti - privatumo politikoje.

EU Cookie Directive plugin by www.channeldigital.co.uk